SCHEMBL17331484

SCHEMBL17331484

c1ccc(-c2c(CNc3ncnc4[nH]cnc34)cn3ccccc23)nc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.37
▸ LMNA P02545 3/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ CDK2 P24941 2/20 0.36
▸ CCNE1 P24864 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ CASP6 P55212 2/20 0.36
▸ TSHR P16473 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ PTK2 Q05397 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CDK1 P06493 5/20 0.31
▸ SYK P43405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17331476 0.88 LMNA (0.38) RECQLLMNAALOX15HTTCDK2
SCHEMBL17331869 0.85 ALOX15 (0.38) RECQLLMNAALOX15HTTCDK2
SCHEMBL17331851 0.82 PIK3CD (0.39) LMNAALOX15HTTCDK5CASP6
SCHEMBL17331965 0.79 PIK3CD (0.45) —
SCHEMBL17331578 0.77 RECQL (0.39) RECQLLMNAALOX15HTTCDK2
SCHEMBL17331838 0.73 CDK2 (0.41) RECQLLMNACDK2CDK5TSHR
SCHEMBL30850618 0.72 RECQL (0.65) RECQLLMNAHTTTSHRSMN1; SMN2
SCHEMBL15426196 0.72 RECQL (0.65) RECQLLMNAHTTTSHRSMN1; SMN2
SCHEMBL17331428 0.72 KDM4E (0.38) LMNAALOX15HTTTSHRTP53
SCHEMBL1443711 0.71 LMNA (0.66) LMNAALOX15HTTCDK2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3157920-B1 INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-08-07 — — EP claimed
EP-3157920-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2017-04-26 — — EP claimed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 — — US claimed
WO-2015193263-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-23 — — WO claimed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 — — US claimed
EP-3157920-B1 INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-08-07 — — EP disclosed
EP-3157920-B1 INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-08-07 — — EP disclosed
EP-3157920-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2017-04-26 — — EP disclosed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 — — US disclosed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 — — US disclosed
US-9527869-B2 Indolizine derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-12-27 — — US disclosed
WO-2015193263-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-23 — — WO disclosed
WO-2015193263-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-23 — — WO disclosed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 — — US disclosed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 — — US disclosed
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361100-A1 INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS PIP4K2B, PIP5K1B, PIP4K2A RECQL 1586/4885LMNA 4372/4885ALOX15 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback